Geraldino-PardillaLPerel-WinklerAMiceliJ, et al.Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. Lupus2019; 28: 862–867.
2.
Costedoat-ChalumeauNAmouraZHulotJS, et al.Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54: 3284–3290.
3.
Costedoat-ChalumeauNAmouraZHulotJS, et al.Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis2007; 66: 821–824.
4.
LiuLHFevrierHBGoldfienRHemmerlingAHerrintonLJ. Understanding nonadherence with hydroxychloroquine therapy in systemic lupus erythematosus. J Rheumatol2019; 46: 1309–1315.
5.
KuznikABencinaMSvajgerUJerasMRozmanBJeralaR. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol2011; 186: 4794–4804.
6.
CrowMK. Type I interferon in the pathogenesis of lupus. J Immunol2014; 192: 5459–5468.
7.
RainsfordKDParkeALClifford-RashotteMKeanWF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology2015; 23: 231–269.
8.
Oliveira-SantosMVeraniJFKlumbEMAlbuquerqueEM. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus2011; 20: 320–329.
9.
GustafssonLLWalkerOAlvanG, et al.Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol1983; 15: 471–479.
